Oral administration of Chinese herbal medicine during gestation period for preventing hemolytic disease of the newborn due to ABO incompatibility: A systematic review of randomized controlled trials

BACKGROUND: About 85.3% of hemolytic disease of the newborn (HDN) is caused by maternal-fetal ABO blood group incompatibility. However, there is currently no recommended “best” therapy for ABO incompatibility during pregnancy. OBJECTIVES: To systematically assess the safety and effectiveness of oral...

Descripción completa

Detalles Bibliográficos
Autores principales: Cao, Huijuan, Wu, Ruohan, Han, Mei, Caldwell, Patrina Ha Yuen, Liu, Jian-Ping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5515403/
https://www.ncbi.nlm.nih.gov/pubmed/28719639
http://dx.doi.org/10.1371/journal.pone.0180746

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5515403/
https://www.ncbi.nlm.nih.gov/pubmed/28719639
http://dx.doi.org/10.1371/journal.pone.0180746

Ejemplares similares